Latent Autoimmune Diabetes Mellitus In Adult: Disease Bioinformatics
Latent Autoimmune Diabetes Mellitus in Adult (LADA) is a late onset form of type 1 diabetes. Because of its late onset, it has been referred to as diabetes 1.5. However, like type 1 diabetes, Latent Autoimmune Diabetes Mellitus is caused by the immune system killing cells in the pancreas. Approximately 5-20% of individuals diagnosed with type 2 diabetes obtain islet autoantibodies (typically GADA) which are characteristic to type 1 diabetes but not type 2. These individuals respond more quickly to insulin treatments and can be classified as having Latent Autoimmune Diabetes Mellitus in Adult. Individuals with LADA are considered to have type 1 diabetes and many do not require insulin right away, but will with time.
Latent Autoimmune Diabetes Mellitus In Adult Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Latent Autoimmune Diabetes Mellitus In Adult below!
For more information on how to use Laverne, please read the How to Guide.
We have 1242 products for the study of Latent Autoimmune Diabetes Mellitus In Adult that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Latent Autoimmune Diabetes Mellitus In Adult is also known as Latent Autoimmune Diabetes Mellitus In Adult (lada).
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.